limitations of using influenza vaccine

Influenza Vaccine is recommended for persons above 6 months of age to protect against influenza infections we have two limitations of using influenza vaccine and we need to know how to overcome both of them

limitations of using influenza vaccine

limitations of using influenza vaccine

 

Febrile Seizures due to TIV and PCV13

Seizures are a very annoying problem and to have a close person developed with febrile seizure due to vaccination is something panicking that happened in 2-5% of children develop febrile seizures, and almost all of them recovered very quickly with no permanent illness. The rate of reportable febrile seizures due to influenza vaccination TIV (trivalent inactivated vaccine) start to increase by the influenza season 2010-2011this was mainly reported in Australia 9/ 1000 doses, so the advisory committee on immunization practice didn’t recommend using the same vaccine for children below 9 years

The risk increased for children aged 6 months to four years on the same day the child receive the vaccine to one day after, concomitant administration of pneumococcal conjugate vaccine (PCV13) will increase the possibility of the development of the febrile seizures with the high peak approximately of 16 months age

No recognized Risk was documented for children above 5 years old and no new recommendation for restricting the influenza vaccination TIV of Pneumococcal vaccination PCV13 vaccination but due to the rate occurred in Australia during the season 2010-2011the (ACIP) Advisory Committee on Immunization Practices not recommending Alfuria the TIV produced by the CSL Biotherapies to be licensed for children below 9 years old

 

Anaphylactic reactions due to influenza vaccination

 

Rarely Severe allergic and anaphylactic reactions may happen due to some vaccine ingredients now days some inoculation of virus prepares all available influenza vaccines into chicken eggs, so more cautious when administering influenza vaccination to persons with a history of egg allergy.

The (ACIP) Advisory Committee on Immunization Practices recommending the following to overcome this problem:

1. If person experienced only hives after exposure to egg or its products the following measures need to be applied:

A) Using LAIV (Life attenuated Influenza Vaccine,) should be substituted by TIV.

B) The health care provider which is administering the vaccine has to be familiar with the symptoms and signs of egg allergy and management.

C) After receiving the vaccination dose the person has to be observed for at least 30 min.

 

2. Severe symptoms developed due to egg reactions as recurrent emesis, angioedema or respiratory distress and more severely symptomatic persons who need epinephrine and another emergency intervention, mainly persons who develop the response immediately or sin short duration (minutes to hours) they are more vulnerable to have a severe reaction. Those persons have to refer to a physician who is experienced in the management of anaphylactic reaction conditions for risk assessment.

3. All vaccines should be administered in well-equipped settings for rapid recognition and management of anaphylaxis is available.

 

4. Tolerance to egg and egg products does not exclude egg allergy. It can be confirmed by a consistent medical history of adverse reactions to eggs and egg products, also skin and/ or blood testing for immunoglobulin E antibodies to egg proteins.

 

5. It is contraindicated to give the vaccine for a person with previous severe allergic reaction to influenza vaccine.

 

Reference

Join our mailing list to receive our weekly updates